Research – Accelerating Digital Transformation in Pharma with IDMP

The report examines the status of the implementation of Identification of Medicinal Products (IDMP) standards in global pharma and the role of the IDMP Ontology in accelerating digital transformation.

The European Medicines Agency (EMA) continues to advance the implementation of IDMP standards, a regulatory framework that will become mandatory across the EU, with the FDA likely to follow close behind. Failure to implement IDMP could lead to a number of risks including regulatory penalties, inefficiencies in operations and threats to patient safety.

Key findings from the report:

• 43% of companies said they plan to implement IDMP Ontology this year
• 89% of companies recognize the long-term value of IDMP beyond compliance
• Pharmacovigilance is no longer seen as key to the success of IDMP even though it was its original purpose

The survey was conducted by the Pistoia Alliance, ACCURIDS and MAIN5 and supported by the award-winning IDMP Ontology project with participants from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer and Novartis.